EGFR and non-small cell lung carcinoma: The limitations of this study include the lack of an external validation cohort; there is no public or clinical data set equivalent to that use in this study with regular long-term follow-up and TCRβ sequencing in patients with stage II/III NSCLC with an EGFR mutation who received adjuvant therapy, including gefitinib and chemotherapy.